Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KDM6B | O15054 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL994930 | 0.86 | LOXL2 (0.42) | LOXL2TDP1L3MBTL1KDM6BKDM4C | |
| SCHEMBL4204738 | 0.79 | CYP2D6 (0.35) | TDP1L3MBTL1KDM6BKDM4CCYP2D6 | |
| SCHEMBL244894 | 0.78 | TDP1 (0.38) | TDP1L3MBTL1KDM6BKDM4CCYP2D6 | |
| SCHEMBL6729852 | 0.77 | L3MBTL1 (0.36) | TDP1L3MBTL1KDM6BKDM4CCYP2D6 | |
| SCHEMBL1044868 | 0.76 | GAA (0.37) | TDP1L3MBTL1KDM6BKDM4CCYP2D6 | |
| SCHEMBL25328626 | 0.76 | KMT2A (0.37) | TDP1L3MBTL1 | |
| SCHEMBL7505763 | 0.74 | SMN1; SMN2 (0.36) | TDP1L3MBTL1 | |
| SCHEMBL31558464 | 0.74 | SMN1; SMN2 (0.36) | TDP1L3MBTL1 | |
| SCHEMBL28498139 | 0.73 | CA12 (0.35) | TDP1L3MBTL1CYP2D6CYP3A4CYP19A1 | |
| SCHEMBL18865581 | 0.73 | TDP1 (0.33) | TDP1L3MBTL1KDM6BKDM4CCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304537-A1 | HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | REPARE THERAPEUTICS INC. (CA) | 2025-10-02 | — | — | US | disclosed |
| CN-119894872-A | Heteroarenes, pharmaceutical compositions containing heteroarenes, and methods of use thereof | 修复治疗公司 | 2025-04-25 | — | — | CN | disclosed |
| EP-4526293-A1 | HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | Repare Therapeutics Inc. (CA) | 2025-03-26 | — | — | EP | disclosed |
| WO-2023220831-A1 | HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | REPARE THERAPEUTICS INC. (CA) | 2023-11-23 | — | — | WO | disclosed |
| US-20090042908-A1 | AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR BETA-SECRETASE MODULATION | WYETH (US) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304537-A1 | HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | CSNK1A1, CSNK1G1, CSNK2A1 | LOXL2 3458/4885TDP1 533/4885L3MBTL1 3552/4885 |
| US-20090042908-A1 | AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR BETA-SECRETASE MODULATION | BACE1, BACE2, APP | LOXL2 2414/4885TDP1 582/4885L3MBTL1 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.